Open Trial of Miglitol in Type 2 Diabetic Patients Treated With Biguanide
NCT ID: NCT00334503
Last Updated: 2008-10-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
INTERVENTIONAL
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Miglitol
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Criteria for postprandial plasma glucose and HbA1c are met
Exclusion Criteria
* Patients treated with other antidiabetic drugs or Insulin
20 Years
69 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sanwa Kagaku Kenkyusho Co., Ltd.
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Study Group, Clinical Development Dept.
Role: STUDY_DIRECTOR
Sanwa Kagaku Kenkyusho Co., Ltd.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Aichi, , Japan
Chiba, , Japan
Fukuoka, , Japan
Gunma, , Japan
Hokkaido, , Japan
Ibaraki, , Japan
Kagoshima, , Japan
Kanagawa, , Japan
Kumamoto, , Japan
Miyazaki, , Japan
Osaka, , Japan
Ōita, , Japan
Saitama, , Japan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MG1009
Identifier Type: -
Identifier Source: org_study_id